Table 1.
Autoantibody ELISA titers and antibody-mediated CaMKII activation results in sera from patients diagnosed with PANDAS.
| Patient # | α-D1R | α-D2R | α-Lysoganglioside-GM1 | α-Tubulin | CaMKII Activation | ASO | ANA | Anti-DNase B |
|---|---|---|---|---|---|---|---|---|
| 1 | 16,000 | 16,000 | 160 | 1,000 | 154.0 | 0 | 0 | 0 |
| 2 | 8,000 | 4,000 | 160 | 1,000 | 112.0 | 403 | 1.0 | 397 |
| 3 | 16,000 | 16,000 | 320 | 2,000 | 149.0 | 180 | 0 | 103 |
| 4 | 2,000 | 4,000 | 640 | 2,000 | 136.7 | 692 | 1.7 | 650 |
| 5 | 2,000 | 4,000 | 160 | 1,000 | 177.7 | 267 | 0 | 580 |
| 6 | 2,000 | 2,000 | 160 | 1,000 | 145.7 | 0 | 1.6 | 0 |
| 7 | 4,000 | 4,000 | 160 | 1,000 | 120.8 | 206 | 1.1 | 126 |
| 8 | 4,000 | 8,000 | 160 | 2,000 | 192.3 | 575 | 1.4 | 956 |
| 9 | 1,000 | 2,000 | 160 | 1,000 | 168.5 | 36 | 0 | 112 |
| 10 | 8,000 | 16,000 | 320 | 2,000 | 216.5 | 0 | 2.0 | 106 |
| 11 | 1,000 | 2,000 | 320 | 500 | 108.4 | 39 | 0 | 194 |
| 12 | 4,000 | 4,000 | 20 | 500 | 109.0 | 0 | 0 | 96 |
| 13 | 4,000 | 4,000 | 160 | 500 | 136.0 | 283 | 0 | 450 |
| 14 | 4,000 | 4,000 | 160 | 1,000 | 127.0 | 0 | 0 | 0 |
| 15 | 8,000 | 16,000 | 160 | 500 | 173.0 | 0 | 2.0 | 0 |
| 16 | 8,000 | 16,000 | 320 | 500 | 169.0 | 485 | 0 | 205 |
| 17 | 8,000 | 8,000 | 640 | 2,000 | 125.0 | 379 | 0 | 104 |
| 18 | 16,000 | 16,000 | 320 | 2,000 | 167.0 | 843 | 1.8 | 420 |
| 19 | 4,000 | 4,000 | 320 | 2,000 | 112.0 | 601 | 0 | 615 |
| 20 | 4,000 | 4,000 | 320 | 1,000 | 197.0 | 37 | 0 | 196 |
| 21 | 2,000 | 16,000 | 320 | 2,000 | 152.3 | 455 | 0 | 366 |
| 22 | 2,000 | 8,000 | 320 | 1,000 | 204.5 | 395 | 1.2 | 164 |
| 23 | 8,000 | 8,000 | 640 | 1,000 | 178.6 | 533 | 1.2 | 0 |
| 24 | 4,000 | 8,000 | 640 | 1,000 | 179.6 | 307 | 0 | 499 |
| 25 | 4,000 | 16,000 | 640 | 2,000 | 95.1 | 96 | 4.3 | 642 |
| 26 | 2,000 | 2,000 | 160 | 2,000 | 160.2 | 20 | 0 | 0 |
| 27 | 4,000 | 4,000 | 160 | 500 | 180.1 | 55 | 0 | 352 |
| 28 | 4,000 | 8,000 | 20 | 1,000 | 187.6 | 671 | 1.3 | 629 |
| 29 | 4,000 | 8,000 | 160 | 1,000 | 189.6 | 183 | 1.6 | 286 |
| 30 | 4,000 | 8,000 | 640 | 1,000 | 209.4 | 265 | 0 | 617 |
| 31 | 1,000 | 2,000 | 80 | 500 | 124.4 | 0 | 0 | 0 |
| 32 | 4,000 | 4,000 | 160 | 500 | 144.0 | 174 | 0 | 185 |
| 33 | 4,000 | 4,000 | 160 | 1,000 | 133.0 | 0 | 0 | 88 |
| 34 | 8,000 | 16,000 | 160 | 500 | 157.9 | 1110 | 1.2 | 1310 |
| 35 | 1,000 | 8,000 | 320 | 1,000 | 128.6 | 875 | 0 | 624 |
| Number of positive results | 25/35 | 9/35 | 6/35 | 10/35 | 25/35 | 21/35 | 13/35 | 13/35 |
| Percent of positive results | 71.4% | 25.7% | 17.1% | 28.6% | 71.4% | 60.0% | 37.1% | 37.1% |
| Total panel positivity | 32/35 PANDAS cases were positive (91.4% sensitivity in SERA) | |||||||
D1R, dopamine receptor D1, positive ≥ 4,000; D2R, dopamine receptor D2L, positive ≥ 16,000; lysoganglioside, positive ≥ 640; tubulin, positive ≥ 2,000; CaMKII, calcium/calmodulin-dependent protein kinase, positive ≥ 130%; ASO, anti-streptolysin O, positive ≥ 167; ANA anti-nuclear antibodies, positive = >1; anti-DNase B, positive >375.
Bold = positive result or neuronal panel-positive patient.
“0” = undetectable level of antibody.